Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Atorvastatin 40 mg daily for 12 months reduces cardiovascular events in lymphoma patients treated with anthracyclines.
Read Full NewsTake 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 5, 2025.
Following stiripentol’s market authorization in Japan in November 2012, a postmarketing surveillance study was conducted in all patients with Dravet syndrome who initiated treatment.
A study reveals EEG and MRI biomarkers in MOGAD patients with epilepsy, highlighting potential early indicators for refractory epilepsy and improved treatment outcomes.
Despite the availability of antiseizure medications approved for Dravet syndrome, a recent survey presented at AES 2025 showed that these therapies remain underutilized in patients.
Serum Albumin Levels Can Predict Increased Cancer Risk in Hemodialysis
1.
Is Laughter Good for Blood Glucose Control?
2.
A study suggests that you should disregard the "pack-years" when determining your eligibility for lung cancer screening.
3.
How Social Determinants of Health Are Linked to Outcomes in Multiple Myeloma
4.
In 18 States, alcohol exclusion laws are still in effect.
5.
Year in Review: Chronic Lymphocytic Leukemia
1.
The Statistical Horizon of Colorectal Cancer: From Global Trends to Precision Therapies and Colorectal Cancer 2025 Forecasts
2.
Tertiary Lymphoid Structures in Cancer: Advancing Therapeutic Implications
3.
The Essential Roadmap for Nutritional Excellence in Head and Neck Cancer Care
4.
Understanding the HAS-BLED Score: What It Is and Why It Matters
5.
Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2
2.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Further Discussion on A New Perspective
3.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
4.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
5.
Virtual Case Study on Elephantiasis of Lower Limb- An Initiative by Hidoc Dr.
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge